Kyverna Therapeutics, Inc., was incorporated in Delaware on June 14, 2018 under the name BAIT Therapeutics, Inc., and changed its name to Kyverna Therapeutics, Inc., in October 2019. The company is a patient-centric clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The company's goal is to bring disease-modifying therapeutic benefits to patients with autoimmune diseases through a patient-centered approach, a broad platform, insights into the treatment of immune diseases, and lessons learned from the successful application of cell therapy in the medical field.
